Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
ABSTRACT Tuberculosis is a global health problem that causes the death of approximately 1.5 million people worldwide each year (WHO, p. 1–126, Global Tuberculosis Report, 2015). Treatment of drug-susceptible tuberculosis requires combination antimicrobial therapy with a minimum of four antimicrobial...
Guardado en:
Autores principales: | Christopher A. Kerantzas, William R. Jacobs |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/718788eb54c14dd5981a50ca56d82753 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Future of Bacteriophage Therapy Will Promote Antimicrobial Susceptibility
por: Olivia Williams Barber, et al.
Publicado: (2021) -
The Origin of Mucosal Immunity: Lessons from the Holobiont <italic toggle="yes">Hydra</italic>
por: Katja Schröder, et al.
Publicado: (2016) -
Postprimary Tuberculosis and Macrophage Necrosis: Is There a Big ConNECtion?
por: Ka-Wing Wong, et al.
Publicado: (2016) -
Antibiotic Tolerance and Combination Therapy
por: David C. Bean, et al.
Publicado: (2015) -
Sterilization by Adaptive Immunity of a Conditionally Persistent Mutant of Mycobacterium tuberculosis
por: Catherine Vilchèze, et al.
Publicado: (2021)